Bringing hope and life-changing therapies to patients & their families
We develop therapies for patients with rare diseases
Our Phase 3 PolarisDMD clinical trial with edasalonexent in muscular dystrophy has been initiated.
June 27, 2019: Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parents Project Muscular Dystrophy 25th Annual Conference
June 21, 2019: Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy
June 18, 2019: Catabasis Pharmaceuticals to Present at Upcoming Symposium on Muscle-Bone Interation in Duchenne Muscular Dystrophy and Parent Project Muscular Dystrophy 25th Annual Conference
We are honored and proud to be members of the Duchenne muscular dystrophy (DMD) community – one that is built on strength and determination.
A potential foundational therapy aimed at improving the lives of all affected by Duchenne.
Join Our Team